Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Aggressive B-Cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06461182
What this trial is testing

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin Lymphoma
Koo Foundation Sun Yat-Sen Cancer Center 15
Not applicableWithdrawnNCT00498667
What this trial is testing

The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

Who this might be right for
Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse
Rambam Health Care Campus
Testing effectiveness (Phase 2)Study completedNCT00644371
What this trial is testing

Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Non-Hodgkin Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 20
Early research (Phase 1)Study completedNCT00323323
What this trial is testing

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Who this might be right for
Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center 24
Early research (Phase 1)Active Not RecruitingNCT05206357
What this trial is testing

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Who this might be right for
Non-hodgkin Lymphoma
Genmab 17
Testing effectiveness (Phase 2)Looking for participantsNCT06649812
What this trial is testing

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type+12 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT01786096
What this trial is testing

A Safety Study of SGN-CD19A for Leukemia and Lymphoma

Who this might be right for
Burkitt LymphomaPrecursor B-cell Lymphoblastic Leukemia-Lymphoma
Seagen Inc. 92
Early research (Phase 1)Looking for participantsNCT05077527
What this trial is testing

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Who this might be right for
AIDS-Related Diffuse Large B-cell LymphomaAIDS-Related Non-Hodgkin LymphomaHIV Infection+12 more
AIDS Malignancy Consortium 20
Testing effectiveness (Phase 2)Study completedNCT02646098
What this trial is testing

CD34+ Selected ASCT for Aggressive Lymphomas

Who this might be right for
Malignant Non-Hodgkin Lymphomas
Insel Gruppe AG, University Hospital Bern 64
Early research (Phase 1)Study completedNCT02471911
What this trial is testing

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Weill Medical College of Cornell University 22
Testing effectiveness (Phase 2)UnknownNCT01653067
What this trial is testing

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Mathias Witzens-Harig 88
Testing effectiveness (Phase 2)Study completedNCT01397825
What this trial is testing

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Who this might be right for
Diffuse Large B-Cell LymphomaTransformed Follicular LymphomaMantle Cell Lymphoma+1 more
Millennium Pharmaceuticals, Inc. 45
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics Incorporated 86
Large-scale testing (Phase 3)Study completedNCT03570892
What this trial is testing

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Novartis Pharmaceuticals 330
Testing effectiveness (Phase 2)Study completedNCT03161054
What this trial is testing

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Who this might be right for
Aggressive Non-Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT05798156
What this trial is testing

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 125
Testing effectiveness (Phase 2)Study completedNCT00881946
What this trial is testing

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Who this might be right for
Hematologic Malignancies
Accenture 73
Testing effectiveness (Phase 2)WithdrawnNCT01101581
What this trial is testing

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Who this might be right for
Non Hodgkin's LymphomaNHLAggressive NHL+1 more
Gilead Sciences
Very early researchEnded earlyNCT00515138
What this trial is testing

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

Who this might be right for
Lymphoma, B-Cell
University of California, San Francisco 7
Early research (Phase 1)Active Not RecruitingNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Next Page
120